Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedMay 12, 2025
DataAggregated Company Financials
Companies67
- 7D-2.1%
- 3M-16.2%
- 1Y0.5%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by PharmaEssentia declining 7.4%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 53% annually.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 12 May 2025 | NT$497.0b | NT$30.3b | -NT$6,456,063,000.00 | 37.4x | -77x | 16.4x |
| Wed, 09 Apr 2025 | NT$437.7b | NT$28.1b | -NT$7,302,014,000.00 | 27.7x | -59.9x | 15.6x |
| Fri, 07 Mar 2025 | NT$545.1b | NT$28.0b | -NT$8,407,141,000.00 | 33.6x | -64.8x | 19.5x |
| Sun, 02 Feb 2025 | NT$550.6b | NT$24.8b | -NT$10,902,841,000.00 | 34.9x | -50.5x | 22.2x |
| Tue, 31 Dec 2024 | NT$509.9b | NT$24.8b | -NT$10,902,841,000.00 | 34.2x | -46.8x | 20.6x |
| Thu, 28 Nov 2024 | NT$507.5b | NT$24.8b | -NT$10,782,551,000.00 | 37.7x | -47.1x | 20.5x |
| Sat, 26 Oct 2024 | NT$545.1b | NT$23.5b | -NT$10,829,095,000.00 | 39x | -50.3x | 23.2x |
| Mon, 23 Sep 2024 | NT$579.7b | NT$23.5b | -NT$10,829,095,000.00 | 35x | -53.5x | 24.7x |
| Wed, 21 Aug 2024 | NT$569.0b | NT$23.6b | -NT$10,755,142,000.00 | 34.4x | -52.9x | 24.2x |
| Fri, 19 Jul 2024 | NT$579.6b | NT$21.9b | -NT$11,110,643,000.00 | 44.6x | -52.2x | 26.4x |
| Sun, 16 Jun 2024 | NT$513.1b | NT$21.9b | -NT$11,110,643,000.00 | 42.7x | -46.2x | 23.4x |
| Tue, 14 May 2024 | NT$454.6b | NT$21.0b | -NT$12,438,653,000.00 | 34.5x | -36.5x | 21.7x |
| Thu, 11 Apr 2024 | NT$463.3b | NT$21.1b | -NT$11,599,476,000.00 | 51.7x | -39.9x | 22x |
| Sat, 09 Mar 2024 | NT$436.2b | NT$20.8b | -NT$9,880,735,000.00 | 38.8x | -44.1x | 21x |
| Mon, 05 Feb 2024 | NT$435.3b | NT$19.9b | -NT$9,830,596,000.00 | 39.3x | -44.3x | 21.9x |
| Wed, 03 Jan 2024 | NT$473.1b | NT$19.8b | -NT$9,748,146,000.00 | 39.6x | -48.5x | 24x |
| Fri, 01 Dec 2023 | NT$485.5b | NT$19.9b | -NT$9,737,975,000.00 | 43.1x | -49.9x | 24.4x |
| Sun, 29 Oct 2023 | NT$472.4b | NT$18.4b | -NT$10,823,013,000.00 | 51.5x | -43.6x | 25.6x |
| Tue, 26 Sep 2023 | NT$482.7b | NT$18.3b | -NT$10,776,417,000.00 | 43.7x | -44.8x | 26.4x |
| Thu, 24 Aug 2023 | NT$479.5b | NT$18.2b | -NT$10,711,380,000.00 | 41.9x | -44.8x | 26.3x |
| Sat, 22 Jul 2023 | NT$481.7b | NT$18.7b | -NT$10,724,655,000.00 | 46x | -44.9x | 25.8x |
| Mon, 19 Jun 2023 | NT$481.1b | NT$18.7b | -NT$10,709,428,000.00 | 42.7x | -44.9x | 25.8x |
| Wed, 17 May 2023 | NT$487.3b | NT$18.6b | -NT$9,763,193,000.00 | 43.8x | -49.9x | 26.2x |
| Fri, 14 Apr 2023 | NT$519.7b | NT$18.5b | -NT$9,600,625,000.00 | 43.2x | -54.1x | 28.1x |
| Sun, 12 Mar 2023 | NT$510.5b | NT$22.3b | -NT$7,221,244,000.00 | 37.4x | -70.7x | 22.9x |
| Tue, 07 Feb 2023 | NT$531.0b | NT$21.8b | -NT$7,778,690,000.00 | 38.7x | -68.3x | 24.3x |
| Thu, 05 Jan 2023 | NT$494.0b | NT$21.8b | -NT$7,778,690,000.00 | 36.7x | -63.5x | 22.7x |
| Sat, 03 Dec 2022 | NT$524.3b | NT$21.8b | -NT$7,522,211,000.00 | 40.3x | -69.7x | 24x |
| Mon, 31 Oct 2022 | NT$434.1b | NT$23.1b | -NT$6,633,590,000.00 | 34.3x | -65.4x | 18.8x |
| Wed, 28 Sep 2022 | NT$565.9b | NT$23.1b | -NT$6,633,590,000.00 | 40.7x | -85.3x | 24.5x |
| Fri, 26 Aug 2022 | NT$611.3b | NT$23.0b | -NT$6,443,294,000.00 | 42.2x | -94.9x | 26.6x |
| Sun, 24 Jul 2022 | NT$545.5b | NT$22.5b | -NT$5,642,821,000.00 | 30.3x | -96.7x | 24.2x |
| Tue, 21 Jun 2022 | NT$507.0b | NT$22.5b | -NT$5,642,821,000.00 | 31.1x | -89.9x | 22.5x |
| Thu, 19 May 2022 | NT$506.3b | NT$22.0b | -NT$5,837,558,000.00 | 31.3x | -86.7x | 23x |
Price to Earnings Ratio
-86.7x
Current Industry PE
- Investors are pessimistic on the Taiwanese Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 23.3x is higher than the industry's current PS ratio of 16.4x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Taiwanese Biotech compare with similar industries?
| TW Market | 0.52% | |
| Healthcare | -0.54% | |
| Biotech | -2.08% | |
| Biotech | -2.08% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6550 Polaris Group | NT$42.10 | 3.8% +NT$1.2b | -40.3% | PS303.1x | |
| 4162 PharmaEngine | NT$91.00 | 3.8% +NT$474.1m | -1.7% | PE7.5x | |
| 6696 Lin BioScience | NT$119.50 | 3.5% +NT$330.7m | 30.9% | PB3.5x | |
| 4174 OBI Pharma | NT$39.25 | 2.9% +NT$289.3m | -35.9% | PS164.7x | |
| 6617 Gongwin Biopharm Holdings | NT$100.00 | 2.0% +NT$252.1m | -45.9% | PS393.4x |